Objective: To assess the effects and safety of recombinant human GH (rhGH) in GH deficient (GHD) children with Rathke cyst.
Methods: The clinical data of 12 GHD children aged from 512 years old, whose radiologic diagnosis showed Rathke cyst during Jan 2010Dec 2012 in our hospital, were analyzed retrospectively. rhGH was given subcutaneously to each enrolled child with a night dose of 0.1 IU/kg six to seven times a week for 1230 months. The serum biochemical indices as well as endocrine hormone level were detected regularly. The clinical data before and after treatment were compared, including height, weight, growth velocity, height SDs, IGF1, bone age and the magnetic resonance imaging result.
Results: With rhGH treatment, a significant increase(P<0.01) of growth velocity in all 12 children, from 4.06±0.61 to 9.86±4.01 cm, was observed in the first 12 months. Meanwhile the height SDS increased obviously from −3.31±1.47 to −2.83±1.36 (P<0.01). In addition, IGF1 rose from (186.73±73.32) μg/l to (436.78±208.60) μg/l (P<0.01), with IGFBP3 from (4.32±0.96) mg/l to (5.63±1.45) mg/l. The peak values of both IGF1 and IGFBP3 were within normal limits. During the treatment and the follow-up period, the biochemical indices were normal and the volumes of the Rathke cysts didnt increase.
Conclusion: The treatment of low level rhGH in GHD children with Rathke cyst was demonstrated effective in this study. Moreover, GH treatment is safe when fully evaluated and closely monitored.
20 - 22 Sep 2014
European Society for Paediatric Endocrinology